BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

Francesco Panza, Madia Lozupone, Vincenzo Solfrizzi, Rodolfo Sardone, Carla Piccininni, Vittorio Dibello, Roberta Stallone, Gianluigi Giannelli, Antonello Bellomo, Antonio Greco, Antonio Daniele, Davide Seripa, Giancarlo Logroscino, Bruno P. Imbimbo

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Introduction: The amyloid hypothesis of Alzheimer’s disease (AD) affirms that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represent the major pathological event of the disease. Several anti-Aβ small organic molecules, monoclonal antibodies and antigens were developed to interfere with Aβ production and clearance, including β–site amyloid precursor protein cleaving enzyme (BACE) inhibitors, blocking the first enzymatic step of Aβ formation. All these approaches, including BACE inhibitors, have failed in large randomized clinical trials (RCTs) in mild-to-moderate AD, but further studies are now being carried out in patients at early AD stages and in asymptomatic subjects at risk of developing AD. Areas covered: The paper provides a comprehensive review of BACE inhibitors for AD treatment, focusing on the most advanced compounds in Phase III RCTs. Expert commentary: BACE inhibitors inhibited robustly, and dose-dependently, Aβ formation in cerebrospinal fluid of AD patients, but without cognitive, clinical, or functional benefit in large RCTs. BACE inhibition may be not sufficient to decrease brain Aβ plaques and aggregates. Indeed, several BACE inhibitors were found to be poorly tolerated and some of them failed also in patients with prodromal AD. This may indicate that blocking the formation of nascent Aβ is not useful in AD.

Original languageEnglish
Pages (from-to)847-857
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume18
Issue number11
DOIs
Publication statusPublished - Nov 2 2018

Fingerprint

Alzheimer Disease
Randomized Controlled Trials
Therapeutics
Amyloid
Phase III Clinical Trials
Amyloid beta-Protein Precursor
Brain
Enzyme Inhibitors
Cerebrospinal Fluid
Monoclonal Antibodies
Antigens

Keywords

  • atabecestat
  • CNP520
  • Dementia
  • elenbecestat
  • lanabecestat
  • lifestyle
  • mild cognitive impairment
  • verubecestat
  • β-amyloid
  • β-secretase inhibitors

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., ... Imbimbo, B. P. (2018). BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics, 18(11), 847-857. https://doi.org/10.1080/14737175.2018.1531706

BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. / Panza, Francesco; Lozupone, Madia; Solfrizzi, Vincenzo; Sardone, Rodolfo; Piccininni, Carla; Dibello, Vittorio; Stallone, Roberta; Giannelli, Gianluigi; Bellomo, Antonello; Greco, Antonio; Daniele, Antonio; Seripa, Davide; Logroscino, Giancarlo; Imbimbo, Bruno P.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 11, 02.11.2018, p. 847-857.

Research output: Contribution to journalReview article

Panza, F, Lozupone, M, Solfrizzi, V, Sardone, R, Piccininni, C, Dibello, V, Stallone, R, Giannelli, G, Bellomo, A, Greco, A, Daniele, A, Seripa, D, Logroscino, G & Imbimbo, BP 2018, 'BACE inhibitors in clinical development for the treatment of Alzheimer’s disease', Expert Review of Neurotherapeutics, vol. 18, no. 11, pp. 847-857. https://doi.org/10.1080/14737175.2018.1531706
Panza, Francesco ; Lozupone, Madia ; Solfrizzi, Vincenzo ; Sardone, Rodolfo ; Piccininni, Carla ; Dibello, Vittorio ; Stallone, Roberta ; Giannelli, Gianluigi ; Bellomo, Antonello ; Greco, Antonio ; Daniele, Antonio ; Seripa, Davide ; Logroscino, Giancarlo ; Imbimbo, Bruno P. / BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. In: Expert Review of Neurotherapeutics. 2018 ; Vol. 18, No. 11. pp. 847-857.
@article{7387b79c1a70430ab5a8b43f048bf3c7,
title = "BACE inhibitors in clinical development for the treatment of Alzheimer’s disease",
abstract = "Introduction: The amyloid hypothesis of Alzheimer’s disease (AD) affirms that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represent the major pathological event of the disease. Several anti-Aβ small organic molecules, monoclonal antibodies and antigens were developed to interfere with Aβ production and clearance, including β–site amyloid precursor protein cleaving enzyme (BACE) inhibitors, blocking the first enzymatic step of Aβ formation. All these approaches, including BACE inhibitors, have failed in large randomized clinical trials (RCTs) in mild-to-moderate AD, but further studies are now being carried out in patients at early AD stages and in asymptomatic subjects at risk of developing AD. Areas covered: The paper provides a comprehensive review of BACE inhibitors for AD treatment, focusing on the most advanced compounds in Phase III RCTs. Expert commentary: BACE inhibitors inhibited robustly, and dose-dependently, Aβ formation in cerebrospinal fluid of AD patients, but without cognitive, clinical, or functional benefit in large RCTs. BACE inhibition may be not sufficient to decrease brain Aβ plaques and aggregates. Indeed, several BACE inhibitors were found to be poorly tolerated and some of them failed also in patients with prodromal AD. This may indicate that blocking the formation of nascent Aβ is not useful in AD.",
keywords = "atabecestat, CNP520, Dementia, elenbecestat, lanabecestat, lifestyle, mild cognitive impairment, verubecestat, β-amyloid, β-secretase inhibitors",
author = "Francesco Panza and Madia Lozupone and Vincenzo Solfrizzi and Rodolfo Sardone and Carla Piccininni and Vittorio Dibello and Roberta Stallone and Gianluigi Giannelli and Antonello Bellomo and Antonio Greco and Antonio Daniele and Davide Seripa and Giancarlo Logroscino and Imbimbo, {Bruno P.}",
year = "2018",
month = "11",
day = "2",
doi = "10.1080/14737175.2018.1531706",
language = "English",
volume = "18",
pages = "847--857",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

AU - Panza, Francesco

AU - Lozupone, Madia

AU - Solfrizzi, Vincenzo

AU - Sardone, Rodolfo

AU - Piccininni, Carla

AU - Dibello, Vittorio

AU - Stallone, Roberta

AU - Giannelli, Gianluigi

AU - Bellomo, Antonello

AU - Greco, Antonio

AU - Daniele, Antonio

AU - Seripa, Davide

AU - Logroscino, Giancarlo

AU - Imbimbo, Bruno P.

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Introduction: The amyloid hypothesis of Alzheimer’s disease (AD) affirms that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represent the major pathological event of the disease. Several anti-Aβ small organic molecules, monoclonal antibodies and antigens were developed to interfere with Aβ production and clearance, including β–site amyloid precursor protein cleaving enzyme (BACE) inhibitors, blocking the first enzymatic step of Aβ formation. All these approaches, including BACE inhibitors, have failed in large randomized clinical trials (RCTs) in mild-to-moderate AD, but further studies are now being carried out in patients at early AD stages and in asymptomatic subjects at risk of developing AD. Areas covered: The paper provides a comprehensive review of BACE inhibitors for AD treatment, focusing on the most advanced compounds in Phase III RCTs. Expert commentary: BACE inhibitors inhibited robustly, and dose-dependently, Aβ formation in cerebrospinal fluid of AD patients, but without cognitive, clinical, or functional benefit in large RCTs. BACE inhibition may be not sufficient to decrease brain Aβ plaques and aggregates. Indeed, several BACE inhibitors were found to be poorly tolerated and some of them failed also in patients with prodromal AD. This may indicate that blocking the formation of nascent Aβ is not useful in AD.

AB - Introduction: The amyloid hypothesis of Alzheimer’s disease (AD) affirms that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represent the major pathological event of the disease. Several anti-Aβ small organic molecules, monoclonal antibodies and antigens were developed to interfere with Aβ production and clearance, including β–site amyloid precursor protein cleaving enzyme (BACE) inhibitors, blocking the first enzymatic step of Aβ formation. All these approaches, including BACE inhibitors, have failed in large randomized clinical trials (RCTs) in mild-to-moderate AD, but further studies are now being carried out in patients at early AD stages and in asymptomatic subjects at risk of developing AD. Areas covered: The paper provides a comprehensive review of BACE inhibitors for AD treatment, focusing on the most advanced compounds in Phase III RCTs. Expert commentary: BACE inhibitors inhibited robustly, and dose-dependently, Aβ formation in cerebrospinal fluid of AD patients, but without cognitive, clinical, or functional benefit in large RCTs. BACE inhibition may be not sufficient to decrease brain Aβ plaques and aggregates. Indeed, several BACE inhibitors were found to be poorly tolerated and some of them failed also in patients with prodromal AD. This may indicate that blocking the formation of nascent Aβ is not useful in AD.

KW - atabecestat

KW - CNP520

KW - Dementia

KW - elenbecestat

KW - lanabecestat

KW - lifestyle

KW - mild cognitive impairment

KW - verubecestat

KW - β-amyloid

KW - β-secretase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85055613528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055613528&partnerID=8YFLogxK

U2 - 10.1080/14737175.2018.1531706

DO - 10.1080/14737175.2018.1531706

M3 - Review article

C2 - 30277096

AN - SCOPUS:85055613528

VL - 18

SP - 847

EP - 857

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 11

ER -